Physician profile
Michael Choi
NPI 1881232429
$18,970.24
in general payments reported to CMS, 2019-2025
34 companies · $8,049 in 2025
The $8,049 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $2,783 · 2023: $3,940 · 2024: $3,955 · 2025: $8,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Travel and Lodging: $2,247 · Consulting Fee: $555 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,018.26 |
| Travel and Lodging | $2,247.12 |
| Consulting Fee | $555.00 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,742.19 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $2,409.84 | 2022-2025 | Ingrezza |
| Abbvie INC. | $2,252.39 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,248.53 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $1,238.33 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $1,236.26 | 2022-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,205.40 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,088.99 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $977.88 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $784.57 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $700.23 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $638.86 | 2022-2025 | Auvelity, Sunosi |
| Indivior INC. | $500.05 | 2022-2025 | Perseris, Sublocade |
| Corium, LLC | $458.63 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $324.88 | 2022-2025 | Trintellix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $324.58 | 2022-2025 | Xelstrym, Secuado |
| Medtronic, INC. | $146.84 | 2021-2022 | |
| Biogen, INC. | $111.72 | 2024-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $83.30 | 2023-2024 | Quviviq |
| Tris Pharma INC | $54.56 | 2023 | Dyanavel Xr |
| Biohaven Pharmaceuticals, INC. | $53.59 | 2021 | |
| Boston Scientific Corporation | $51.12 | 2021 | |
| Ironshore Pharmaceuticals INC. | $50.85 | 2024 | |
| Harmony Biosciences LLC | $43.60 | 2024 | |
| Merck Sharp & Dohme LLC | $41.82 | 2023 | Belsomra |
| Luye Pharma (USA) LTD. | $38.08 | 2025 | Erzofri Extended-Release |
| Sumitomo Pharma America, INC. | $24.21 | 2023 | Latuda |
| Owp Pharmaceuticals, INC. | $23.96 | 2025 | Subvenite |
| Ibsa Pharma INC. | $23.07 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $21.88 | 2025 | Lumryz |
| Tersera Therapeutics LLC | $19.38 | 2021 | |
| Chiesi USA, INC. | $19.29 | 2021 | |
| Allergan, INC. | $15.76 | 2022 | |
| Almatica Pharma LLC | $15.60 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.